Before you can access ASH's online program, you must agree to the following:
Last updated January 16, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.

602.O2.8 Disordered Gene Expression in Hematologic Malignancy, Including Epigenetic Regulation (II)

Monday, December 8, 2008: 3:30 PM-5:30 PM
Golden Gate Hall (San Francisco Marriott)
Moderators:
Marķa-Eugenia Figueroa and Lucio H. Castilla, PhD
3:30 PM
Evi1 Promotes Leukemogenesis by Anti-Apoptotic Rather Than Differentiation-Blocking Effects in Murine MLL-AF9 LeukemiaClinically Relevant Abstract

Ashish Kumar, MBBS, PhD, Quanzhi Li, PhD*, Wendy A Hudson*, Thien N Sam*, Weili Chen* and John H Kersey, MD*

Masonic Cancer Center, University of Minnesota, Minneapolis, MN

3:45 PM
Genetics and Epigenetics of the PU.1 Upstream Regulatory Element: AML1 Binding Sites Are Critical for Leuekmia Induced by the AML/ETO9a Fusion Oncogene

Pu Zhang, MD1, Gang Huang2*, Alex Ebralidze1*, Jun-Yan Zhang1*, Annalisa DiRuscio1*, Chris Hetherington1*, Elena Levantini1* and Daniel G. Tenen1*

1Harvard Medical School, Harvard Institutes of Medicine, Harvard Stem Cell Institute, Boston, MA
2Hema. & Onco., Memorial Sloan-Kettering Cancer Center, New York, NY

4:00 PM
Integrative Genomic Analysis Reveals Aberrant Epigenetic Marks in MDS That Can Be Seen in Peripheral Blood Leucocytes

Li Zhou1*, Joanna B. Opalinska1, Davendra P. Sohal1*, Yongkai Mo1, Suman Kambhampati2*, Simrit Parmar3*, Christina Alencar1*, Christoph Heuck1*, Ivette Vigoda1*, Chun Ng1*, Perry Pahanish1*, Swati Goel1*, Carolina Schinke1*, Lawrence Cytryn4, Ellen Friedman4*, Maria E Figueroa5, Amittha Wickrema, PhD6, John Greally1* and Amit Verma1

1Albert Einstein College of Medicine, Bronx, NY
2Veterans Affairs, Kansas University Medical Center, Kansas City, MO
3UT Southwestern, Dallas
4Montefiore Med. Center, Bronx, NY
5Weill Cornell Medical College, New York, NY
6University of Chicago, Chicago, IL

4:15 PM
Specific Promoter CpG Island Methylation Patterns Identify Different Subgroups of MLL - Rearranged Infant Acute Lymphoblastic Leukemia, and Define Clinical Outcome

Dominique JPM Stumpel, MD1*, Pauline Schneider1*, Eddy HJ van Roon, MSc2*, Judith M Boer, PhD2*, Renee X Menezes, PhD1*, Rob Pieters, MD, PhD3 and Ronald W. Stam, Ph.D.1*

1Dept. of Pediatric Onc./Hem., Erasmus Medical Center, Rotterdam, Netherlands
2Leiden Genome Technology Center and Center for Human and Clinical Genetics, Leiden University Medical Center, Leiden, the Netherlands, Leiden
3Dept. of Pediatric Hem./Onc., Erasmus Medical Center, Rotterdam, Netherlands

4:30 PM
Comprehensive Genomic and DNA Methylation Analysis in Twins with ETV6-RUNX1 Acute Lymphoblastic Leukemia

Manoo Bhakta, MD1*, Mathias Ehrich, MD2*, Eric J. Gratias, MD1, James R. Downing, MD3* and Charles G Mullighan, MBBS(Hons), MSc, MD4

1University of Tennessee at Chattanooga and T.C. Thompson Children's Hospital, Chattanooga, TN
2Sequenom, Inc., San Diego, CA
3Administration, St. Jude Children's Research Hospital, Memphis, TN
4Pathology, St. Jude Children's Research Hospital, Memphis, TN

4:45 PM
Microrna 124 and Its Role in Response to Epigenetic Therapy in Patients with Acute Mylogenous Leukemia and Myelodysplastic Syndrome

Ryan J Castoro*, Mhair Dekmezian*, Amanda J Saraf*, Yoshiyuki Watanabe*, Woonbok Chung*, Samih El Adhab*, Jaroslav Jelinek* and Jean-Pierre Issa, MD

Dept. of Leukemia, University of Texas, Houston, TX

5:00 PM
Differences Between Normal and Leukemic Stem Cell-Specific Methylome Indicates Aberrantly Silenced Genes Involved in the Pathogenesis of Malignant Evolution

Rebecca D Ganetzky, B.A.1*, Ying Jiang, M.D., Ph.D.2*, Jeffrey Falk, Ph.D.3*, Mingjie Jin, Ph.D.3*, Dongyan Liu, M.S.3*, Soledad Negrotto, Ph.D.4*, Yogen Saunthararajah, M.D.4 and Jaroslaw P. Maciejewski, MD, PhD4

1Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland Clinic, Cleveland, OH
2Hematologic Oncology and Blood Disorders/Experimental Hematology and Hematopoiesis Section, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
3Aviva Systems Biology, San Diego, CA
4Experimental Hematology and Hematopoiesis, Cleveland Clinic Foundation, Cleveland, OH

5:15 PM
Epigenetic Manipulation of Cancer Testis Antigen (CTA) Expression: A Strategy for Manipulating the Graft-Versus Leukaemia Response in Patients Allografted for Haematological Malignancies

Tatjana Stankovic, MD., PhD1*, Andrew McLarnon1*, Angelo Agathanggelou1*, Oliver Goodyear1*, Charles Craddock2* and Paul Moss, MBBS, PhD, FRCP1

1CRUK Institute for Cancer Studies, University of Birmingham, Birmingham, United Kingdom
2Centre for Clinical Haematology, University Hospital Birmingam, Birmingham, United Kingdom

*signifies non-member of ASH